ProQR Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
ProQR Therapeutics has a total shareholder equity of €32.9M and total debt of €4.4M, which brings its debt-to-equity ratio to 13.5%. Its total assets and total liabilities are €118.1M and €85.2M respectively.
Key information
13.5%
Debt to equity ratio
€4.44m
Debt
| Interest coverage ratio | n/a |
| Cash | €96.15m |
| Equity | €32.85m |
| Total liabilities | €85.20m |
| Total assets | €118.05m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: PRQR N's short term assets (€101.8M) exceed its short term liabilities (€37.3M).
Long Term Liabilities: PRQR N's short term assets (€101.8M) exceed its long term liabilities (€47.9M).
Debt to Equity History and Analysis
Debt Level: PRQR N has more cash than its total debt.
Reducing Debt: PRQR N's debt to equity ratio has reduced from 15% to 13.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PRQR N has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: PRQR N has sufficient cash runway for 2.4 years if free cash flow continues to grow at historical rates of 12.6% each year.